Joshua Brown, Pharm.D., Ph.D., M.S.
Assistant Professor
About Joshua Brown
Joshua Brown joined the Department of Pharmaceutical Outcomes and Policy as an assistant professor in 2016. He has experience in clinical pharmacy, health economics and outcomes research, and pharmacoepidemiology across academic, pharmaceutical industry, and managed care. His past and ongoing clinical interests have been in the cardiovascular and hematology/oncology therapeutic areas including comparative effectiveness and safety research with a focus on anticoagulation and quality of care in thrombotic conditions such as atrial fibrillation, venous thromboembolism, and cancer. His current research program and collaborations focus on research methods for pharmacoepidemiologic and pharmacoeconomic generic and biosimilar evaluations, developing real-world evidence for drug-drug interactions, and drug repurposing studies (e.g. aging and Parkinson’s Disease). \His academic work has been funded by the NIH, FDA, Bill & Melinda Gates Foundation, and the PhRMA Foundation in addition to contracts with pharmaceutical industry. Josh has published over 100 research articles and holds several editorial positions with high impact specialty journals in pharmacy and cardiovascular diseases and is actively involved in AMCP, ISPE, and ISPOR scientific societies. Dr. Brown was awarded as the AMCP Foundation’s “New Practitioner” for his early career contributions to managed care pharmacy.
Accomplishments
Publications
Grants
Education
Contact Details
- Business:
- (352) 294-8593
- Business:
- joshua.brown@cop.ufl.edu
Recent news
UF researchers report mixed results in safety study of drugs seen as possible COVID-19 therapeutics
University of Florida College of Pharmacy researchers studying the safety of two classes of drugs touted as potential therapeutics for COVID-19 report mixed results.
UF leadership in the International Society for Pharmacoepidemiology
UF Faculty and alumni took over several leadership roles in the society during the 35th International Conference on Pharmacoepidemiology in Philadelphia. Along with Dr. Almut Winterstein, Dr. Juan Hincapie-Castillo also…
Study finds moderate reduction carisoprodol use following DEA Schedule IV classification
UF researchers reviewed more than 13 million patients using carisoprodol, a powerful muscle relaxant.
Dr. Josh Brown receives AMCP’s 2019 New Practitioner Award
AMCP gives the award to a member who has made a significant contribution to managed care pharmacy within five years of graduation.